Passage Bio (PASG) Price & Analysis

Compare

642 Followers

PASG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.12 - $26.60

Previous CloseN/A

Volume182.24K

Average Volume (3M)34.06K

Market Cap

$24.96M

Enterprise Value-$7.52M

Total Cash (Recent Filing)$57.63M

Total Debt (Recent Filing)$24.73M

Price to Earnings (P/E)―

Beta1.68

Next Earnings

Nov 18, 2025

EPS Estimate

-2.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.96

Shares Outstanding3,120,295

10 Day Avg. Volume31,129

30 Day Avg. Volume34,060

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.30

Enterprise Value/Revenue-2.34

Enterprise Value/Gross Profit-18.58

Enterprise Value/Ebitda0.14

Forecast

1Y Price Target

$39.00

Price Target Upside387.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyThe prevention of neurodegeneration is suggested by a smaller increase in plasma NfL levels in treated patients compared to untreated patients.

Regulatory ProgressThe plan to seek FDA feedback on the design of the registrational study remains unchanged, and the recent agreement between Alector and the FDA on including plasma PGRN as a co-primary endpoint in the ongoing Ph3 study in FTD-GRN is seen as positive for PASG.

Safety ManagementPatient 9 was treated with no material safety events reported, indicating a possible improvement in safety management.

Bears Say

Competitive LandscapeThe peak penetration assumption is decreased from 25% to 15% due to the evolving competitive landscape.

Safety ConcernsThe emergence of a new SAE (pulmonary embolism) in Patient 8 following treatment with Dose 2 has raised safety concerns.

Valuation ImpactThe risk-adjusted valuation of PBFT02 decreased significantly from ~$1B to $283M, impacting the overall valuation.

Passage Bio News

Promising Developments and Strong Financial Outlook Reinforce Buy Rating for Passage Bio

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Passage Bio, boosting the price target to $40.00....

2M ago

PASG

Passage Bio price target lowered to $67 from $260 at Canaccord

Canaccord lowered the firm’s price target on Passage Bio (PASG) to $67 from $260 and keeps a Buy...

2M ago

PASG

Passage Bio Reports Q2 2025 Progress and Financials

Passage Bio, Inc. ( ($PASG) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

PASG

Passage Bio Reports Promising Q2 2025 Financial Results

An update from Passage Bio ( ($PASG) ) is now available. On August 12, 2025, Passage Bio reported...

2M ago

PASG

Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year

“We continue to be encouraged by the emerging data from our upliFT-D clinical trial, which underscore the potential...

2M ago

PASG

Passage Bio expects cash to fund operations into Q1 of 2027

Cash, cash equivalents and marketable securities were $57.6 million as of June 30, 2025, as compared to $91.8...

2M ago

PASG

Passage Bio Regains Nasdaq Compliance with Stock Price

Passage Bio ( ($PASG) ) just unveiled an update. On July 28, 2025, Passage Bio, Inc. announced that...

2M ago

PASG

Passage Bio Announces Reverse Stock Split Effective July 14

Passage Bio ( ($PASG) ) has shared an announcement. Passage Bio announced a 1-for-20 reverse stock split of...

3M ago

PASG

Upcoming Stock Splits This Week (July 14 to July 18) – Stay Invested

These are the upcoming stock splits for the week of July 14 to July 18, based on TipRanks’ Stock...

3M ago

GORV

HTOO

Passage Bio trading halted, news pending

19:50 EDT Passage Bio (PASG) trading halted, news pending Published first on TheFly – the ultimate source for...

3M ago

PASG

Passage Bio announces 1-for-20 reverse stock split

Passage Bio (PASG) has approved a reverse stock split of the company’s outstanding shares of common stock at...

3M ago

PASG

Optimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns

In a report released on June 25, Yun Zhong from Wedbush maintained a Buy rating on Passage Bio...

3M ago

PASG

Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating

Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Passage Bio (PASG – Research Report), retaining...

3M ago

PASG

Passage Bio Releases Promising Interim Data for PBFT02

The latest announcement is out from Passage Bio ( ($PASG) ). On June 23, 2025, Passage Bio announced...

3M ago

PASG

PASG FAQ

What was Passage Bio’s price range in the past 12 months?

Passage Bio lowest stock price was $5.12 and its highest was $26.60 in the past 12 months.

What is Passage Bio’s market cap?

Passage Bio’s market cap is $24.96M.

When is Passage Bio’s upcoming earnings report date?

Passage Bio’s upcoming earnings report date is Nov 18, 2025 which is in 49 days.

How were Passage Bio’s earnings last quarter?

Passage Bio released its earnings results on Aug 12, 2025. The company reported -$2.96 earnings per share for the quarter, beating the consensus estimate of -$4.04 by $1.08.

Is Passage Bio overvalued?

According to Wall Street analysts Passage Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Passage Bio pay dividends?

Passage Bio does not currently pay dividends.

What is Passage Bio’s EPS estimate?

Passage Bio’s EPS estimate is -2.81.

How many shares outstanding does Passage Bio have?

Passage Bio has 3,120,295 shares outstanding.

What happened to Passage Bio’s price movement after its last earnings report?

Passage Bio reported an EPS of -$2.96 in its last earnings report, beating expectations of -$4.04. Following the earnings report the stock price went down -4.915%.

Which hedge fund is a major shareholder of Passage Bio?

Currently, no hedge funds are holding shares in PASG

Passage Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-88.27%

Trailing 12-Months

Asset Growth

-36.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Passage Bio

Passage Bio (PASG) is a biotechnology company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company specializes in gene therapies, utilizing cutting-edge technologies to address unmet medical needs in neurology. With a robust pipeline of therapies in various stages of development, Passage Bio aims to deliver precision medicine solutions to patients with debilitating genetic conditions.

Passage Bio (PASG) Earnings & Revenues

Historic Earnings Reports

PASG Stock 12 Month Forecast

Average Price Target

$39.00

▲(387.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","20":"$20","36":"$36","52":"$52","68":"$68"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,20,36,52,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.74,10.452307692307691,15.164615384615384,19.876923076923077,24.589230769230767,29.301538461538463,34.01384615384615,38.72615384615385,43.43846153846154,48.15076923076923,52.863076923076925,57.575384615384614,62.2876923076923,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.74,8.298461538461538,10.856923076923078,13.415384615384616,15.973846153846154,18.53230769230769,21.090769230769233,23.64923076923077,26.207692307692305,28.76615384615385,31.324615384615385,33.88307692307692,36.441538461538464,{"y":39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.74,6.067692307692308,6.395384615384615,6.723076923076923,7.050769230769231,7.378461538461538,7.706153846153846,8.033846153846154,8.361538461538462,8.689230769230768,9.016923076923078,9.344615384615384,9.672307692307692,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >